Factors associated with the healthcare expenditures of patients with multiple sclerosis in urban areas of China estimated by a generalized estimating equation

References

• Thompson AJ, Baranzini SE, Geurts J, et al. Multiple sclerosis. Lancet. 2018;391:1622–1636.
   PubMed Web of Science ®Google Scholar
• Brownlee WJ, Hardy TA, Fazekas F, et al. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017;389(10076):1336–1346.
   PubMed Web of Science ®Google Scholar
• Collaborators GBDMS. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18(3):269–285.
   PubMed Web of Science ®Google Scholar
• Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 2006;5(11):932–936.
   PubMed Web of Science ®Google Scholar
• Halawani AT, Zeidan ZA, Kareem AM, et al. Sociodemographic, environmental and lifestyle risk factors for multiple sclerosis development in the western region of Saudi Arabia. A matched case control study. Saudi Med J. 2018;39(8):808–814.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123–1136.
   PubMed Web of Science ®Google Scholar
• Ernstsson O, Gyllensten H, Alexanderson K, et al. Cost of illness of multiple sclerosis - A systematic review. PLoS One. 2016;11(7):e0159129.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J. Lindgren P, et al. Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis. Eur J Health Econ. 2006;7(Suppl 2):S5–13.
   PubMedGoogle Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler. 2012;18(2):7–15.
   PubMedGoogle Scholar
• Kobelt G, Eriksson J, Phillips G, et al. The burden of multiple sclerosis 2015: methods of data collection, assessment and analysis of costs, quality of life and symptoms. Mult Scler. 2017;23(2):4–16.
   PubMedGoogle Scholar
• Kolasa K. How much is the cost of multiple sclerosis-systematic literature review. Przegl Epidemiol. 2013;67(1):75–9, 157–60.
   Google Scholar
• Sicras-Mainar A, Ruiz-Beato E, Navarro-Artieda R, et al. Impact on healthcare resource utilization of multiple sclerosis in Spain. BMC Health Serv Res. 2017;17(1):854.
   PubMedGoogle Scholar
• Liu X, Cui Y, Han J. Estimating epidemiological data of multiple sclerosis using hospitalized data in Shandong province, China. Orphanet J Rare Dis. 2016;11(1):73.
   PubMedGoogle Scholar
• Gyllensten H, Wiberg M, Alexanderson K, et al. Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age. Eur J Health Econ. 2018;19(3):435–446.
   PubMed Web of Science ®Google Scholar
• Piccinni C, Ronconi G, Calabria S, et al. Healthcare resources utilisation in primary progressive multiple sclerosis. Neurol Sci. 2018;39(7):1169–1174.
   PubMed Web of Science ®Google Scholar
• OECD. Purchasing power parities (PPP) (indicator); 2019 [cited 2019 Dec 12]. Available from: https://data.oecd.org/conversion/exchange-rates.htm#indicator-chart
   Google Scholar
• Rotstein Z, Hazan R, Barak Y, et al. Perspectives in multiple sclerosis health care: special focus on the costs of multiple sclerosis. Autoimmun Rev. 2006;5(8):511–516.
   PubMed Web of Science ®Google Scholar
• Carney P, O’Boyle D, Larkin A, et al. Societal costs of multiple sclerosis in Ireland. J Med Econ. 2018;21(5):425–437.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66(11):1696–1702.
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Colman S, O’Leary B, et al. The economic impact of multiple sclerosis in Australia in 2010. Mult Scler. 2013;19(12):1640–1646.
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, van Munster ET, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: the costs and utilities of MS patients in The Netherlands. J Med Econ. 2013;16(7):939–950.
   PubMedGoogle Scholar
• Fogarty E, Walsh C, McGuigan C, et al. Direct and indirect economic consequences of multiple sclerosis in Ireland. Appl Health Econ Health Policy. 2014;12(6):635–645.
   PubMedGoogle Scholar
• Chinese Society of Immunology Neuroimmunology Branch. Consensus of Chinese experts on diagnosis and treatment of multiple sclerosis (version 2018). Chin J Neuroimmunol Neurol. 2018;25(6):387–393.
   Google Scholar
• National Health Commission. Notice on issuing guidelines for diagnosis and treatment of rare diseases (2019 Edition) [ cited 2019 Feb 28]. Available from: http://www.gov.cn/fuwu/2019-02/28/content_5369203.htm
   Google Scholar
• Rare disease development center (CORD). China rare disease drug access report; 2019 [cited 2019 Mar 12]. Available from: http://www.doc88.com/p-7186423334030.html
   Google Scholar
• The national medical insurance bureau and the ministry of human resources and social security. print and publish the 2019 national medical insurance negotiation admission drug list [ cited 2019 Nov 28]. Available from: http://www.gov.cn/xinwen/2019-11/28/content_5456660.htm
   Google Scholar
• He Y, Du M, Gao Y, et al. Astragaloside IV attenuates experimental autoimmune encephalomyelitis of mice by counteracting oxidative stress at multiple levels. PloS One. 2013;8(10):e76495.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Yang Y, Li J. Does acupuncture help patients with spasticity? A narrative review. Ann Phys Rehabil Med. Epub ahead of print. 2018 Nov 5. DOI:10.1016/j.rehab.2018.09.010
   PubMed Web of Science ®Google Scholar
• Cheng XJ, Xu LZ. Review of the diagnosis and clinical features of multiple sclerosis in China. Neurosci Bull. 2009;25:38–42.
   PubMed Web of Science ®Google Scholar
• Song L, Zhou QH, Wang HL, et al. Chinese herbal medicine adjunct therapy in patients with acute relapse of multiple sclerosis: A systematic review and meta-analysis. Complement Ther Med. 2017;31(4):71–81.
   PubMedGoogle Scholar
• He AJ, Wu S. Towards universal health coverage via social health insurance in China: systemic fragmentation, reform imperatives, and policy alternatives. Appl Health Econ Health Policy. 2017;15(6):707–716.
   PubMed Web of Science ®Google Scholar
• Meng Q, Fang H, Liu X, et al. Consolidating the social health insurance schemes in China: towards an equitable and efficient health system. Lancet. 2015;386(10002):1484–1492.
   PubMed Web of Science ®Google Scholar
• Min R, Zhang X, Fang P, et al. Health service security of patients with 8 certain rare diseases: evidence from China’s national system for health service utilization of patients with healthcare insurance. Orphanet J Rare Dis. 2019;14(1):204.
   PubMed Web of Science ®Google Scholar
• He J, Song P, Kang Q, et al. Overview on social security system of rare diseases in China. Biosci Trends. 2019;13(4):314–323.
   PubMed Web of Science ®Google Scholar
• Svendsen B, Grytten N, Bo L, et al. The economic impact of multiple sclerosis to the patients and their families in Norway. Eur J Health Econ. 2018;19(9):1243–1257.
   PubMed Web of Science ®Google Scholar
• Amankwah N, Marrie RA, Bancej C, et al. Multiple sclerosis in Canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts. Health Promot Chronic Dis Prev Can. 2017;37(2):37–48.
   PubMed Web of Science ®Google Scholar
• Stevenson V, Gras A. Bárdos J and Broughton J. The high cost of spasticity in multiple sclerosis to individuals and society. Mult Scler. 2015;21(12):1583–1592.
   PubMed Web of Science ®Google Scholar
• Yu W, Li M, Ye F, et al. Patient preference and choice of healthcare providers in Shanghai, China: a cross-sectional study. BMJ Open. 2017;7(10):e016418.
   PubMed Web of Science ®Google Scholar
• National Health Commission. Notice on the registration of diagnosis and treatment information for rare disease cases. [ cited 2019 Oct 21]. Available from: http://www.gov.cn/xinwen/2019-10/21/content_5442768.htm
   Google Scholar